Captopril (100 mg/kg, q.d., orally, from the 6th week of age) strongly inhibits genetic hypertension development (GHD) and this effect persists up to 12 weeks after treatment discontinuation. However, during these 12 weeks, systolic blood pressure and heart weight/body weight ratio (HW/BW) show a similar trend to slowly increase. We have investigated whether identical phenomena develop at the vascular level. Captopril strongly increased vascular mesenteric compliance, reduced aortic wall weight, mesenteric arterial wall lumen ratio and active contractile ability during treatment period and these effects were still observed up to 7 weeks after treatment interruption although there was a slight but progressive reduction in their intensity. Thus captopril opposes the structural and functional vascular and cardiac alterations which accompany GHD and this effect contributes to a large extent to the long-lasting preventive effects of the drug against GHD.
Download full-text PDF |
Source |
---|
PLoS One
January 2025
Faculty of Medicine, Division of Population Health and Applied Health Sciences, Clinical Epidemiology Unit, Memorial University, St. John's, Newfoundland and Labrador, Canada.
Background: The number of persons living with multimorbidity-defined as the co-occurrence of at least two chronic conditions in the same individual-is growing globally, especially in developed countries. Traditionally, this increase has been attributed to a growing aging population, sedentary lifestyle, obesity, low socioeconomic status, and individual genetic susceptibility.
Objective: To investigate the prevalence and associated risk factors of the most common multimorbidity (MCM) among Canadian middle-aged and older adults.
JCEM Case Rep
February 2025
Pediatric Endocrinology, Diabetology and Metabolism, Bern University Hospital, 3010 Bern, Switzerland.
3β-Hydroxysteroid dehydrogenase 2 deficiency (3βHSD2D) is a rare form of congenital adrenal hyperplasia (CAH) with variable clinical presentation. We describe a 46, XY child with ambiguous genitalia and CAH without apparent adrenal insufficiency due to 2 novel heterozygous variants in the gene (c.779C > T/p.
View Article and Find Full Text PDFFront Public Health
January 2025
Department of Computer Science, Division of Science, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
J Endocr Soc
January 2025
Cellular and Molecular Endocrinology Laboratory LIM/25, Division of Endocrinology and Metabolism, Clinicas Hospital, School of Medicine, University of Sao Paulo, 01246-903 Sao Paulo, Brazil.
Human puberty is a dynamic biological process determined by the increase in the pulsatile secretion of GnRH triggered by distinct factors not fully understood. Current knowledge reveals fine tuning between an increase in stimulatory factors and a decrease in inhibitory factors, where genetic and epigenetic factors have been indicated as key players in the regulation of puberty onset by distinct lines of evidence. Central precocious puberty (CPP) results from the premature reactivation of pulsatile secretion of GnRH.
View Article and Find Full Text PDFClin Appl Thromb Hemost
January 2025
Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background: Venous thromboembolism (VTE) comprises deep vein thrombosis (DVT) and pulmonary embolism (PE). Chronic thromboembolic pulmonary hypertension (CTEPH) typically arises from acute pulmonary embolism. The pathogenesis of them involves multiple risk factors such as genetic predisposition.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!